Studies related to and

A Randomized, Double-blind Placebo-controlled Trial Of Oral Creatine Monohydrate Augmentation For Enhanced Response To A Selective Serotonin Reuptake Inhibitor In Women With Major Depressive Disorder

Effect Decrease
Trial Design Double blind
Trial Length n/a
Number of Subjects 52
Gender n/a
Notes for this study:
5 g/day as adjunct therapy (alongside SSRIs) showed promise in reducing depression as assessed by the Hamilton Rating Scale for Depression (HRSD) and was safe over the 8 weeks the study lasted.

Open-label Adjunctive Creatine For Female Adolescents With SSRI-resistant Major Depressive Disorder: A 31-phosphorus Magnetic Resonance Spectroscopy Study

Effect Decrease
Trial Design Cohort
Trial Length n/a
Number of Subjects 15
Gender n/a
Notes for this study:
4 g/day given to adolescent females suffering from depression was able to significantly reduce depression (56%) over 8 weeks. Supplementation was not compared to placebo, however, which means the number may be inflated, as the benefits from creatine and from the placebo effect are confounded.

Creatine Monohydrate In Resistant Depression: A Preliminary Study

Effect Decrease
Trial Design Cohort
Trial Length n/a
Number of Subjects 8
Gender n/a
Notes for this study:
Treated for 4 weeks with 3-5g creatine monohydrate.

Depression improved in all subjects, but both subjects with Bipolar disorder experienced worsening symptoms.